Market News & Trends
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 & Establishes Clinical Advisory Board
Mediar Therapeutics, Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced that, following FDA clearance of its investigational…
Arecor & Medtronic Diabetes Establish Collaboration to Develop Novel Thermostable Insulin for Implantable Pump Delivery
Medtronic to fund Arecor’s development of Arestat-enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination….
5 Prime Sciences Announces Strategic Collaboration With Lilly in Cardio-Metabolic Diseases
5 Prime Sciences recently announced a strategic collaboration with Eli Lilly and Company dedicated to accelerating target discovery and early development in the field of…
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
Bluejay Therapeutics recently announced the successful closure of a $182 million Series C financing round. This capital infusion will accelerate the clinical development of BJT-778,…
Attovia Therapeutics Raises $105 Million in Financing
Attovia Therapeutics recently announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the company since its launch…
Akoya Biosciences & NeraCare Enter Exclusive Agreement to Enable Personalized Therapy Selection for Early Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will…
Curia & Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
Curia and Carterra Inc. recently announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott….
Siren Biotechnology & Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology and Catalent Inc. recently entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene….
On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023
Alongside its dynamic growth, Vetter announced that it achieved its sustainability goals for 2023. The Contract Development & Manufacturing Organization (CDMO) recently became a member…
ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering First-in-Class Antiviral Innate Immunomodulator
ENA Respiratory recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 18/112091 titled “Novel molecules” covering claims for….
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR Therapeutics NV recently announced new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical proof of concept data for…
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
Therini Bio, Inc. recently announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases. The data…
FDA Grants Orphan Drug Designation to Biompharma’s Microbiome-Modifying Biologic
BIOM Pharmaceutical Corporation recently announced Bi104, its innovative drug product, has been granted orphan-drug designation by the US FDA for the treatment of Angelman syndrome…
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001), the company's lead clinical development program, for…
Derm-Biome Pharmaceuticals & TransBIOtech Awarded $450,000 Applied Research & Development Grant
Derm-Biome Pharmaceuticals, Inc. recently announced that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and…
Eledon Announces Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals, Inc. recently announced the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a…
MannKind Receives FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease
MannKind Corporation recently announced the US FDA has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung…
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
Lantern Pharma Inc. recently announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics, to optimize the development of its first-in-class protein disulfide isomerase (PDI) inhibitor drug…
EyeDNA Therapeutics Announces Positive 24-month Data From Ongoing Phase 1/2 Trial of HORA-PDE6b Gene Therapy in Patients With Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
eyeDNA Therapeutics recently announced positive 24-month follow-up results from its Phase 1/2 study (NCT03328130) evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy…
Enable Injections Expands Strategic Partnership With Roche
Enable Injections, Inc. recently announced it has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise….
